Wugen, Inc.
Clinical trials sponsored by Wugen, Inc., explained in plain language.
-
New cell therapy tested in patients with Tough-to-Treat blood cancer
Disease control CompletedThis early-stage study tested a new cell therapy called WU-NK-101 in patients with acute myeloid leukemia (AML) that had returned or stopped responding to other treatments. The main goals were to find a safe dose and see how well the body tolerates the treatment. Researchers also…
Phase: PHASE1 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
First human test of 'Off-the-Shelf' cell therapy for tough blood cancers
Disease control CompletedThis study tested the safety and early effectiveness of a new type of cell therapy called WU-CART-007 in adults and adolescents with T-cell leukemia or lymphoma that has come back or not responded to other treatments. The main goals were to find a safe dose and see if the therapy…
Phase: PHASE1 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC